Lu Shi

The safety, efficacy, and treatment outcomes of a combination of low-dose decitabine treatment in patients with recurrent ovarian cancer

M. Brock, Q. Mei, M. Guo, 2017, Oncoimmunology.

Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial

J. Rasko, Q. Mei, L. Dong, 2020, Clinical Cancer Research.

Increased IFNγ+ T Cells Are Responsible for the Clinical Responses of Low-Dose DNA-Demethylating Agent Decitabine Antitumor Therapy

Q. Mei, W. Han, Lin Liu, 2017, Clinical Cancer Research.

Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma.

M. Brock, Q. Mei, W. Han, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

DNA methylation-mediated repression of miR-181a/135a/302c expression promotes the microsatellite-unstable colorectal cancer development and 5-FU resistance via targeting PLAG1.

Q. Mei, M. Guo, Xiaolei Li, 2018, Journal of genetics and genomics = Yi chuan xue bao.

Urinary bladder malignant paraganglioma with vertebral metastasis: a case report with literature review

Wen-Zhi Liu, Xiang Li, Hai-de Gao, 2013, Chinese journal of cancer.

Phase Ib/II study of safety and efficacy of low‐dose decitabine‐primed chemoimmunotherapy in patients with drug‐resistant relapsed/refractory alimentary tract cancer

M. Brock, Q. Mei, M. Guo, 2018, International journal of cancer.

AD-AutoGPT: An Autonomous GPT for Alzheimer's Disease Infodemiology

Quanzheng Li, Tianming Liu, Dajiang Zhu, 2023, ArXiv.